Detalhe da pesquisa
1.
Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial.
Breast Cancer Res Treat
; 133(3): 1067-75, 2012 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-22415477
2.
Splicing profile by capture RNA-seq identifies pathogenic germline variants in tumor suppressor genes.
NPJ Precis Oncol
; 4: 4, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32133419
3.
Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine.
Clin Cancer Res
; 21(19): 4305-11, 2015 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26041745
4.
Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
J Clin Oncol
; 27(18): 2954-61, 2009 Jun 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-19349550
5.
Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy.
J Clin Oncol
; 25(30): 4765-71, 2007 Oct 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-17947724